Modulatory effects of mycobacterial heat-shock protein 70 in DNA vaccination lymphoma

Haematologica

Volumn 90, Issue 1, 2005, Pages 60-65

  Liso, Arcangelo ^a   Benedetti, Roberta ^b   Fagioli, Marta ^b   Mariano, Angela ^b   Falini, Brunangelo ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Heat shock protein; Immunotherapy; Lymphoma; Vaccination

Indexed keywords

DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN IDIOTYPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOMA; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMID; TREATMENT OUTCOME; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY FORMATION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HSP70 HEAT-SHOCK PROTEINS; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; PLASMIDS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, DNA;

EID: 13344269595     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987;139:2825-33.
2. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171-7.
3. Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, et al. Antitumor vaccination: where we stand. Haematologica 2000;85:1172-206.
4. Massaia M. Idiotype vaccination of myeloma patients after chemotherapy. Acta Oncol 2000;39:807-8.
5. Timmerman JM, Levy R. The history of the development of vaccines for the treatment of lymphoma. Clin Lymphoma 2000;1: 129-39.
6. Liso A, Benedetti R, Flenghi L, Falini B. Vaccine therapy of B cell malignancies: different strategies for a novel approach. Leuk Lymphoma 2001;42:881-9.
7. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 1995;145:211-28.
8. Stevenson FK, Zhu D, Spellerberg MB, Rice J, King CA, Thompsett AR, et al. DNA vaccination against cancer antigens. Ernst Schering Res Found Workshop 2000:119-36.
9. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002; 62:5845-52.
10. McCarthy H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-idiotype vaccines. Br J Haematol 2003;123:770-81.
11. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3: 630-41.
12. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80.
13. Manjili MH, Wang XY, Park J, Facciponte JG, Repasky EA, Subjeck JR. Immunotherapy of cancer using heat shock proteins. Front Biosci 2002;7:43-52.
14. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-42.
15. Hsu KF, Hung CF, Cheng WF, He L, Slater LA, Ling M, et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 2001;8:376-83.
16. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Rice CM, et al. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 2001;166:6218-26.
17. Huang Q, Richmond JF, Suzue K, Eisen HN, Young RA. In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4(+) T cell independent. J Exp Med 2000;191:403-8.
18. Wang Y, Kelly CG, Karttunen JT, Whittall T, Lehner PJ, Duncan L, et al. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Immunity 2001;15:971-83.
19. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002;188:147-54.
20. Villinger F. Cytokines as clinical adjuvants: how far are we? Expert Rev Vaccines 2003; 2:317-26.
21. Bergman Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur J Immunol 1977;7:413-7.
22. Eshhar Z, Blatt C, Bergman Y, Heimovich J. Induction of secretion of IgM from cells of the B cell line 38c-13 by somatic cell hybridization. J Immunol 1979;122:2430-4.
23. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996;2:1038-41.
24. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993;90:8392-6.
25. Syrengelas AD, Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 1999;162:4790-5.
26. Desombere I, Meuleman P, Rigole H, Willems A, Irsch J, Leroux-Roels G. The Interferon γ secretion assay: a reliable tool to study interferon γ production at the single cell level. J Immunol Methods 2004;286:167-85.
27. Wong CP, Okada CY, Levy R. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response. J Immunol 1999;162:2251-8.
28. Mellstedt H, Fagerberg J, Frodin JE, Henriksson L, Hjelm-Skoog AL, Liljefors M, et al. Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr Opin Hematol 1999; 6:169-75.
29. McNeel DG, Schiffman K, Disis ML. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1999;93: 2653-9.
30. Ullenhag G, Bird C, Ragnhammar P, Frodin JE, Strigard K, A OI, et al. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Clin Immunol 2001;99:65-74.
31. Ageitos AG, Ino K, Ozerol I, Tarantolo S Heimann DG, Talmadge IE. Restoration of T and NK cell function in GM-CSF mobilized stem cell products from breast cancer patients by monocyte depletion. Bone Marrow Transplant 1997;20:117-23.
32. van Eden W, Koets A, van Kooten P, Prakken B, van der Zee R. Immunopotentiating heat shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine 2003;21:897-901.
33. Przepiorka D, Srivastava PK. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol Med Today 1998;4:478-84.
34. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278:117-20.
35. Wendling U, Paul L, van der Zee R, Prakken B, Singh M, van Eden W. A conserved mycobacterial heat shock protein (hsp) 70 sequence prevents adjuvant arthritis upon nasal administration and induces IL-10-producing T cells that cross-react with the mammalian self-hsp70 homologue. J Immunol 2000;164:2711-7.
36. Liu LJ, Watabe S, Yang J, Hamajima K, Ishii N, Hagiwara E, et al. Topical application of HIV DNA vaccine with cytokme-expression plasmids induces strong antigen-specific immune responses. Vaccine 2001;20:42-8.